StreetAlpha.app
Home › Stocks › RYTM

Rhythm Pharmaceuticals, Inc. (RYTM)

Healthcare
$116.61
▲ +8.49%
LAST CLOSE · NOV 17

Rhythm Pharmaceuticals develops and sells IMCIVREE, a treatment for rare genetic forms of obesity. It last closed at $116.61 on Nov 17, up 8.49% on the day. The average 12-month price target from 8 analysts is $138.88 (+19.1% from the last close), with a high of $166.00 and a low of $114.00. Analyst consensus is Strong Buy, based on the latest ratings from 8 firms (7 buy, 1 hold, 0 sell). In the past 30 days there were 5 dark pool prints totaling $4.3M, the largest $1.3M.

AI Auto Pilots
Is RYTM in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$280.7M
+61.0% vs a year ago
Net income
−$193.8M
−69.0% margin
EPS (diluted)
−$2.91
Free cash flow
−$83.2M
−29.6% margin
Valuation
Market cap
$8.1B
69.3M shares
P/E
–
No P/E while losing money
Price to sales
28.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$40.0M
At Sep 30
Debt
$102.7M
At Sep 30
Shareholder equity
$88.0M
Shares outstanding
69.3M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $3.2M$3.2MFY2021FY2022: $23.6M$23.6MFY2022FY2023: $77.4M$77.4MFY2023FY2024: $130.1M$130.1MFY2024FY2025: $189.8M$189.8MFY2025

From RYTM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 8 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
8firms
7 Buy1 Hold0 Sell
Each firm's latest rating on RYTM in the past 90 days
Average 12-month target
$138.88
▲ 19.1% upside

Based on 8 analysts who set a price target on RYTM in the past 90 days. The average target is $138.88, with a high of $166.00 and a low of $114.00, compared with the last close of $116.61.

Low $114.00Avg $138.88High $166.00
Blue marker: last close $116.61
Highest target$166.00
Average target$138.88
Lowest target$114.00
Latest rating changes
JP MorganTarget lowered
Nov 7Buy$146 → $142
GuggenheimMaintained
Nov 5Buy$147
CitizensTarget raised
Nov 4Buy$160 → $166
NeedhamMaintained
Nov 3Buy$114
HC Wainwright & Co.Maintained
Oct 12Buy$130
DateFirmActionRatingPrice target
Nov 7JP MorganTarget loweredBuy$146 → $142
Nov 5GuggenheimMaintainedBuy$147
Nov 4CitizensTarget raisedBuy$160 → $166
Nov 3NeedhamMaintainedBuy$114
Oct 12HC Wainwright & Co.MaintainedBuy$130
Loading…

Technical Analysis

RYTM · as of the Nov 17 close · updated after every close
Uptrend, nearing overbought

The stock is 13% above its 20 day and 17% above its 50 day average. It is 17% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 64), near overbought. The nearest support is the Pivot at $113.10, and the nearest resistance the swing high (Aug 19) at $118.31.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityHigh, 5.4%/day
Key levels
$122.2052 week high+4.8%
$122.01Pivot R1+4.6%
$118.31Swing high (Aug 19)+1.5%
$116.61Last close
$113.10Pivot−3.0%
$111.42Swing low (Aug 12)−4.5%
$107.70Pivot S1−7.6%
$103.31100 day average−11.4%
$101.2520 day average−13.2%
$97.31200 day average−16.6%
$97.2750 day average−16.6%
$74.5052 week low−36.1%
Indicators
RSI (14)63.50Strong, overbought above 70Neutral
MACD5.47Above its signal lineBullish
Stochastic86.2Near the top of its rangeOverbought
ADX (14)29.7Trending up
Williams %R-5.1Oversold below −80, overbought above −20Overbought
CCI (20)83.6Oversold below −100, overbought above 100Neutral
Rate of change+34.9%Change over 10 sessionsBullish
ATR (14)$6.26Typical daily range, 5.4% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for RYTM

What happened before

See how RYTM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow RYTM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How RYTM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in RYTM in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
5
Notional
$4.3M
Largest print
$1.3M
Loading…

RYTM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲185 buying vs 116 selling
  • ▲Held by funds +2.3 pts
  • ▲Funds holding +27
  • ▲Superinvestors: 4 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding333306+8.8%
In funds' top 1010100.0%
Held by funds114.0%111.7%+2.3 pts
New / increased56 / 12961 / 105+11.4%
Reduced / sold out86 / 30100 / 41−17.7%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RYTM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RYTM is in one of them and how their past RYTM trades turned out.

RYTM in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RYTM in an article yet. Here's the latest on the wider market.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts, in the United States. It sells IMCIVREE, a treatment that acts on the MC4R pathway in the brain, for patients with certain rare genetic forms of obesity, such as Bardet Biedl syndrome. The company is also developing other MC4R agonist treatments for hypothalamic obesity and other rare conditions. Its customers are patients with these rare diseases, along with the physicians and healthcare providers who treat them.

Headquarters
Boston, MA
Founded
2008